

Diffusion Tensor Imaging for Evaluating Postoperative Outcomes of Supratentorial Glioma in the Motor Function Area [Letter]

Theo Moraes Teixeira¹, Luis Filipe de Souza Godoy², Wellingson Silva Paiva¹

¹LIM 62, Division of Neurosurgery, Hospital das Clínicas, University of São Paulo Medical School, São Paulo, Brazil; ²Institute of Radiology, Hospital das Clínicas, University of São Paulo Medical School, São Paulo, Brazil

Correspondence: Wellingson Silva Paiva, LIM 62, Division of Neurosurgery, Hospital das Clínicas, University of São Paulo Medical School, Av. Dr. Enéas Carvalho de Aguiar, 255, São Paulo, 05403-010, Brazil, Email wellingsonpaiva@yahoo.com.br

Dear editor

Gliomas represent about 30% of tumors of the central nervous system (CNS)¹ and, in adults, about 70% of these are supratentorial.² The most successful treatment involves chemotherapy, radiotherapy and surgical resection with at least 2 cm of margin,³ and studying peritumoral white matter pathways preoperatively is relevant enabling early assessment of risk and reduction of neurological complications. Diffusion tensor imaging (DTI) is a tool for mapping relevant axonal tracts since it relies on magnetic resonance imaging (MRI) technology to offer a noninvasive and precise method for individually observing major pathways in the brain.⁴

Duy Hung et al assess if preoperative DTI mapping is a reliable method for predicting motor function impairment after resection.⁵ The article is a retrospective study of 43 patients who underwent navigation-guided surgery for histopathologically confirmed supratentorial glioma in motor function area after preoperative observation with MRI conventional and DTI sequences, all of whom also underwent pre- and postoperative clinical evaluation concerning motor function. It demonstrates a correlation between DTI observed tumoral infiltration and clinical motor impairment levels, showing that patients with greater infiltration tend to have a worst motor function prognosis. They concluded that DTI should be used in a preoperative context for better planning of surgical resection of supratentorial gliomas and predict motor function outcomes.

We deem important to discuss methodological limitations regarding a possible selection bias, DTI analysis, lack of a control group and weak outcome measurement.

The article features a small sample from a single healthcare center, weakening its generalization potential. Also, the selection and inclusion criteria are not clearly defined. The study reports that patient records were surveyed for clinical data, including the pre- and postoperative Karnofsky Performance Status (KPS) score and muscle strength evaluation according to the British Medical Research Council (MRC) scale, but it does not mention how the patients were deemed eligible. We considered this a limitation since several confusion factors may have been overlooked, which could otherwise change the outcome of the study.

Furthermore, DTI observation was based on color hues, which represent the craniocaudally oriented corticospinal tract but also contain thalamocortical radiations to the motor and sensory cortex. Fiber tracking could add conspicuity for detecting corticospinal fibers in corona radiata and their spatial relation with the tumor.

The article does not mention the inclusion of a control group and is based on the comparison of pre- and postoperative motor function, showing that DTI results are predictive of resection-related impairment degree. However, it is relevant to compare postoperative outcome between patients who underwent preoperative DTI with a control group. It is appropriate to investigate if DTI usage could significantly improve postoperative functional outcome.

Finally, the study measures outcome based on the British MRC scale for physical strength and the KPS score for general well-being. Although these are well-established systems, the authors do not explain why they have selected such methods. This can bias the study since patients could experience complications attributable to tumor resection that are not assessed by both scores, especially considering non-motor neurological complications.

Disclosure

The authors report no conflicts of interest in this communication.

References

1. Goodenberger MKL, Jenkins RB. Genetics of adult glioma. *Cancer Genet.* 2012;205(12):613–621. doi:10.1016/S2210-7762(12)00260-8
2. Persaud-Sharma D, Burns J, Trangle J, et al. Disparities in brain cancer in the United States: a literature review of gliomas. *Med Sci.* 2017;5(3):16. doi:10.3390/medsci5030016
3. Iacob G, Dinca EB. Current data and strategy in glioblastoma multiforme. *J Med Life.* 2009;2(4):386. PMID: 20108752.
4. Le Bihan D, Mangin J-F, Poupon C, et al. Diffusion tensor imaging: concepts and applications. *J Magn Reson Imaging.* 2001;13(4):534–546. doi:10.1002/jmri.1076
5. Duy Hung N, Duy Linh N, Ha Vi N, et al. Predictive value of preoperative diffusion tensor imaging for evaluating postoperative outcomes of supratentorial glioma in the motor function area. *Ther Clin Risk Manag.* 2023;19:269–278. doi:10.2147/TCRM.S402622

Dove Medical Press encourages responsible, free and frank academic debate. The content of the Therapeutics and Clinical Risk Management 'letters to the editor' section does not necessarily represent the views of Dove Medical Press, its officers, agents, employees, related entities or the Therapeutics and Clinical Risk Management editors. While all reasonable steps have been taken to confirm the content of each letter, Dove Medical Press accepts no liability in respect of the content of any letter, nor is it responsible for the content and accuracy of any letter to the editor.

Therapeutics and Clinical Risk Management

Dovepress

Publish your work in this journal

Therapeutics and Clinical Risk Management is an international, peer-reviewed journal of clinical therapeutics and risk management, focusing on concise rapid reporting of clinical studies in all therapeutic areas, outcomes, safety, and programs for the effective, safe, and sustained use of medicines. This journal is indexed on PubMed Central, CAS, EMBASE, Scopus and the Elsevier Bibliographic databases. The manuscript management system is completely online and includes a very quick and fair peer-review system, which is all easy to use. Visit <http://www.dovepress.com/testimonials.php> to read real quotes from published authors.

Submit your manuscript here: <https://www.dovepress.com/therapeutics-and-clinical-risk-management-journal>

<https://doi.org/10.2147/TCRM.S428676>